FORMULATION AND IN-VITRO CHARACTERIZATION OF LORNOXICAM TRANSDERMAL MATRIX PATCH

Abstract

Transdermal therapeutic systems are defined as self-contained, discrete dosage forms which, when applied to intact skin, deliver drug(s), through skin, at a controlled rate to systemic circulation. In the present study transdermal patches of Lornoxicam were prepared using hydrophilic polymer and hydrophobic polymer. Transdermal drug delivery system has the potential advantages of avoiding hepatic first pass metabolism, maintaining constant blood levels for a longer period of time, resulting in a reduction of dosing frequency, improved bioavailability, and decreased gastrointestinal irritation that occur due to local contact with gastric mucosa and improved patient compliance. Lornoxicam is a newer NSAID of the oxicam class for the treatment of anti-inflammatory properties in a range of painful and inflammatory conditions, including Rheumatoid arthritis and postoperative pain. Lornoxicam Patch was prepared by the solvent casting method using HPMC various grade and Eudragit RS 100 as a polymer, PEG-400 and Tween 80 uses as plasticizer, Methanol and Dichloromethane used as solvent. LXTMP1 showed desired % Drug Content, Thickness, Folding Endurance, Flatness, Diffusion Study, Sensitivity Study on animal and Kinetic Model Study and better than other seven batches so, it is selected optimized batch.